Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.
Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders.
The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders.
Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 28, 25 | -0.66 Decreased by -6.49 K% | - |
| Nov 22, 24 | -24.19 Decreased by -242.00 K% | -1.17 Decreased by -1.97 K% |
| Jan 9, 24 | -0.12 Decreased by -1.30 K% | -0.03 Decreased by -300.00% |
| Oct 5, 23 | -0.01 Decreased by -116.67% | 0.03 Decreased by -133.33% |
| Oct 5, 23 | -0.01 Increased by +92.32% | 0.03 Decreased by -133.33% |
| Jul 10, 23 | 0.01 Increased by +150.00% | 0.04 Decreased by -75.00% |
| Jul 10, 23 | 0.01 Increased by +150.00% | 0.04 Decreased by -75.00% |
| Apr 27, 23 | 0.06 Increased by +160.00% | 0.02 Increased by +200.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 652.00 K Decreased by -98.94% | -13.28 M Decreased by -214.30% | Decreased by -2.04 K% Decreased by -29.65 K% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -13.48 M Decreased by -219.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 53.63 M Decreased by -24.36% | -85.00 M Decreased by -2.01 K% | Decreased by -158.52% Decreased by -2.69 K% |
| Nov 30, 23 | 53.63 M Decreased by -24.36% | -85.00 M Decreased by -2.01 K% | Decreased by -158.52% Decreased by -2.69 K% |
| Sep 30, 23 | 61.71 M Decreased by -21.39% | -4.22 M Increased by +47.78% | Decreased by -6.85% Increased by +33.56% |
| Aug 31, 23 | 61.71 M Decreased by -21.39% | -4.22 M Increased by +47.78% | Decreased by -6.85% Increased by +33.56% |
| Jun 30, 23 | 70.89 M Decreased by -10.14% | -4.03 M Increased by +14.81% | Decreased by -5.69% Increased by +5.20% |
| May 31, 23 | 70.89 M Decreased by -10.14% | -4.03 M Increased by +14.81% | Decreased by -5.69% Increased by +5.20% |